Проранжировали
Aug. 28th, 2021 11:35 pm![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
chuka_lisМонголы снова порадовали четким подходом.
Они сравнили уровни нейтрализующих антител (к РСЧ) у привитых 4мя разными вакцинами- Pfizer/BioNTech(BNT162b2), AstraZeneca(ChAdOx1-S), Sputnik V(Gam-COVID-Vac) и Sinopharm(BBIBP-CorV) и, кроме этого, как сыворотка привитых "связывается" с шипиками 9ти штаммов вируса ( Alpha (N501Y), Beta (K417N, E484K, N501Y), Gamma (K417T, E484K, N501Y), Delta (L452R, T478K), Epsilon (L452R), Eta/Iota/Zeta (E484K), Kappa (L452R, E484Q), B.1.526.2 (S477N) and P.3 (E484K, N501Y), как и Wuhan-Hu1).
У них вышло, что лучше всего работает вакцина от Файзера, а хуже всех- от Синофарм. Которой, увы, привито почти 90% вакцинированных в стране.
Достоверной разницы в выработке антител в зависимости от пола и возраста выявлено не было (тк большой разброс). Но если говорить о тенденции- то больше антител было у молодых ( до 60 лет) и у женщин.
Более четко выглядели отличия по типу вакцины. Эффективнее всего имумнитет был после прививки BNT162b2, затем ChAdOx1-S, далее Gam-COVID-Vac, и замыкал- BBIBP-CorV.
А если перед прививкой человек еще и болел- то его антитела связывались лучше и их было больше.
Для Файзера- в таком случае антитела вообще блокировали варианты штаммов почти идеально. За ним шел "Спутник" (который для "наивных" по эффективности был на 3 месте). Ну и Синофарм в конце.
Цифры у них только на диаграмках (и в дополниительных материалах), но наглядно видно хорошо (см. рис.1).
We collected plasma specimensin a five-day period from July 3 to 7, 2021fromMongolian participants who had been fully vaccinatedwith one of four Covid vaccines: Pfizer/BioNTech(BNT162b2), AstraZeneca(ChAdOx1-S), Sputnik V(Gam-COVID-Vac) and Sinopharm(BBIBP-CorV). Participants were recruited by public announcement and volunteers were enrolled after signing the consent form approved by the Ethics Review Board at the Ministry of Healthof Mongolia.(SupplementalMaterial). Antibodies were analyzed in the plasmasof 196participants divided between the vaccine groups(47, 50, 45 and 54individuals for Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm, respectively)and selected to balance age, sex and time after second vaccine dose (Figs. S1, S2). We measured antibody blocking ofangiotensin-converting enzyme 2 (ACE2)host receptor protein binding to SARS-CoV-2 spike receptor binding domains(RBD) from nineviral variants of concern or interestaccording to CDC and WHO definitions, using an electrochemiluminescence assay platform from MesoScale Discovery. The RBDs that were tested were (with RBD amino acid changes from Wuhan-Hu1 in parentheses): Alpha (N501Y), Beta (K417N, E484K, N501Y), Gamma (K417T, E484K, N501Y), Delta (L452R, T478K), Epsilon (L452R), Eta/Iota/Zeta (E484K), Kappa (L452R, E484Q), B.1.526.2 (S477N) and P.3 (E484K, N501Y), as well asWuhan-Hu1 ACE2 blocking antibody activity was strikingly different between the vaccines tested.Within each vaccine group, differences were also observed in antibody activity for the differentviral variant antigens, although these were smaller than the differences between the vaccinegroups. The Pfizer/BioNTech vaccine elicited the strongest ACE2 blocking antibody activity,followed by AstraZenecavaccine,thenSputnik V, with the lowest levels fromSinopharm(Fig. 1A).Differences between the vaccine responses were highly significant for most viral variants, although differences between the Sputnik V and AstraZenecadid not always reach significance. ACE2 blocking antibody activity for viral variants of concern or interest showeda consistent hierarchy ofdecreased blocking, with the greatest decrease for the Beta, Gamma and P.3 variants and more modest decreases for the other variants Titers of IgG specific for RBD and spike showed similar results to the ACE2 blocking antibody results, with decreasing titers from Pfizer/BioNTech to AstraZeneca to Sputnik V to Sinopharm (Fig. S3A).The age of vaccine recipientsand proportions of males and females in each group were comparable(Fig. S1). Notably, males had significantly lower ACE2 blocking antibody values than females to the Pfizer/BioNTech and Sinopharm vaccines, but not to the AstraZeneca and Sputnik V vaccines Theserological data from recipients of the four vaccines tested suggested that Sinopharm recipients,who comprise 89.2% ofvaccinated adults in Mongolia, as well as the smallernumber of individuals vaccinated with Sputnik V or AstraZeneca vaccines,could be particularly susceptible to breakthrough infections. Viral genotyping showed that theseinfections were dominated by presumptive Alpha variants withthe N501Y mutation, accounting for 97.3% (177/182)of cases tested. The othersamples were comprised of two samples with the L452R mutation, consistent with several lineages including the Delta variant, and three samples without N501Y, E484K, orL452Rmutations, unlikely to represent variants of concernor interest.Samples containing N501Y were further tested for spike del69_70by RT-qPCR; this characteristic deletion was detected in all (177/177) of these samples, confirming that Sinopharmpost-vaccination cases were caused primarily by theAlpha variant. TheAlpha variant has minimal evasion of antibody responses elicited by Wuhan-Hu1 antigens(Muik et al., 2021)(Fig. 1A), suggesting that the breakthrough infections in Mongolia are related to the overall low antibody levels, rather than being caused by viral variants with greater antibody evasion capabilities.In summary, this direct comparison of vaccine-elicited functional antibody responses to a panel of nine SARS-CoV-2viral variant RBD proteinsindicates that there are marked differences in the serological responses generated by each vaccine, with relatively low antibody titers and ACE2 blocking activity stimulated by the Sinopharmand Sputnik V vaccines, variable levels for the AstraZenecavaccine, and the highest values for the Pfizer/BioNTech vaccine.Most individuals who recover from infection with SARS-CoV-2 after receivingany of the vaccines studied show elevated ACE2 blocking antibody activity, comparable to that seen in uninfected recipients of thePfizer vaccine. Breakthrough infections in Mongolia in June and July 2021 are largely attributable to the more infectious, but not highly immune-evasive Alpha variant
Они сравнили уровни нейтрализующих антител (к РСЧ) у привитых 4мя разными вакцинами- Pfizer/BioNTech(BNT162b2), AstraZeneca(ChAdOx1-S), Sputnik V(Gam-COVID-Vac) и Sinopharm(BBIBP-CorV) и, кроме этого, как сыворотка привитых "связывается" с шипиками 9ти штаммов вируса ( Alpha (N501Y), Beta (K417N, E484K, N501Y), Gamma (K417T, E484K, N501Y), Delta (L452R, T478K), Epsilon (L452R), Eta/Iota/Zeta (E484K), Kappa (L452R, E484Q), B.1.526.2 (S477N) and P.3 (E484K, N501Y), как и Wuhan-Hu1).
У них вышло, что лучше всего работает вакцина от Файзера, а хуже всех- от Синофарм. Которой, увы, привито почти 90% вакцинированных в стране.
Достоверной разницы в выработке антител в зависимости от пола и возраста выявлено не было (тк большой разброс). Но если говорить о тенденции- то больше антител было у молодых ( до 60 лет) и у женщин.
Более четко выглядели отличия по типу вакцины. Эффективнее всего имумнитет был после прививки BNT162b2, затем ChAdOx1-S, далее Gam-COVID-Vac, и замыкал- BBIBP-CorV.
А если перед прививкой человек еще и болел- то его антитела связывались лучше и их было больше.
Для Файзера- в таком случае антитела вообще блокировали варианты штаммов почти идеально. За ним шел "Спутник" (который для "наивных" по эффективности был на 3 месте). Ну и Синофарм в конце.
Цифры у них только на диаграмках (и в дополниительных материалах), но наглядно видно хорошо (см. рис.1).
We collected plasma specimensin a five-day period from July 3 to 7, 2021fromMongolian participants who had been fully vaccinatedwith one of four Covid vaccines: Pfizer/BioNTech(BNT162b2), AstraZeneca(ChAdOx1-S), Sputnik V(Gam-COVID-Vac) and Sinopharm(BBIBP-CorV). Participants were recruited by public announcement and volunteers were enrolled after signing the consent form approved by the Ethics Review Board at the Ministry of Healthof Mongolia.(SupplementalMaterial). Antibodies were analyzed in the plasmasof 196participants divided between the vaccine groups(47, 50, 45 and 54individuals for Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm, respectively)and selected to balance age, sex and time after second vaccine dose (Figs. S1, S2). We measured antibody blocking ofangiotensin-converting enzyme 2 (ACE2)host receptor protein binding to SARS-CoV-2 spike receptor binding domains(RBD) from nineviral variants of concern or interestaccording to CDC and WHO definitions, using an electrochemiluminescence assay platform from MesoScale Discovery. The RBDs that were tested were (with RBD amino acid changes from Wuhan-Hu1 in parentheses): Alpha (N501Y), Beta (K417N, E484K, N501Y), Gamma (K417T, E484K, N501Y), Delta (L452R, T478K), Epsilon (L452R), Eta/Iota/Zeta (E484K), Kappa (L452R, E484Q), B.1.526.2 (S477N) and P.3 (E484K, N501Y), as well asWuhan-Hu1 ACE2 blocking antibody activity was strikingly different between the vaccines tested.Within each vaccine group, differences were also observed in antibody activity for the differentviral variant antigens, although these were smaller than the differences between the vaccinegroups. The Pfizer/BioNTech vaccine elicited the strongest ACE2 blocking antibody activity,followed by AstraZenecavaccine,thenSputnik V, with the lowest levels fromSinopharm(Fig. 1A).Differences between the vaccine responses were highly significant for most viral variants, although differences between the Sputnik V and AstraZenecadid not always reach significance. ACE2 blocking antibody activity for viral variants of concern or interest showeda consistent hierarchy ofdecreased blocking, with the greatest decrease for the Beta, Gamma and P.3 variants and more modest decreases for the other variants Titers of IgG specific for RBD and spike showed similar results to the ACE2 blocking antibody results, with decreasing titers from Pfizer/BioNTech to AstraZeneca to Sputnik V to Sinopharm (Fig. S3A).The age of vaccine recipientsand proportions of males and females in each group were comparable(Fig. S1). Notably, males had significantly lower ACE2 blocking antibody values than females to the Pfizer/BioNTech and Sinopharm vaccines, but not to the AstraZeneca and Sputnik V vaccines Theserological data from recipients of the four vaccines tested suggested that Sinopharm recipients,who comprise 89.2% ofvaccinated adults in Mongolia, as well as the smallernumber of individuals vaccinated with Sputnik V or AstraZeneca vaccines,could be particularly susceptible to breakthrough infections. Viral genotyping showed that theseinfections were dominated by presumptive Alpha variants withthe N501Y mutation, accounting for 97.3% (177/182)of cases tested. The othersamples were comprised of two samples with the L452R mutation, consistent with several lineages including the Delta variant, and three samples without N501Y, E484K, orL452Rmutations, unlikely to represent variants of concernor interest.Samples containing N501Y were further tested for spike del69_70by RT-qPCR; this characteristic deletion was detected in all (177/177) of these samples, confirming that Sinopharmpost-vaccination cases were caused primarily by theAlpha variant. TheAlpha variant has minimal evasion of antibody responses elicited by Wuhan-Hu1 antigens(Muik et al., 2021)(Fig. 1A), suggesting that the breakthrough infections in Mongolia are related to the overall low antibody levels, rather than being caused by viral variants with greater antibody evasion capabilities.In summary, this direct comparison of vaccine-elicited functional antibody responses to a panel of nine SARS-CoV-2viral variant RBD proteinsindicates that there are marked differences in the serological responses generated by each vaccine, with relatively low antibody titers and ACE2 blocking activity stimulated by the Sinopharmand Sputnik V vaccines, variable levels for the AstraZenecavaccine, and the highest values for the Pfizer/BioNTech vaccine.Most individuals who recover from infection with SARS-CoV-2 after receivingany of the vaccines studied show elevated ACE2 blocking antibody activity, comparable to that seen in uninfected recipients of thePfizer vaccine. Breakthrough infections in Mongolia in June and July 2021 are largely attributable to the more infectious, but not highly immune-evasive Alpha variant
![[community profile]](https://www.dreamwidth.org/img/silk/identity/community.png){kind=small}
no subject
Date: 2021-08-29 08:49 pm (UTC)no subject
Date: 2021-08-29 09:47 pm (UTC)no subject
Date: 2021-08-30 03:52 am (UTC)Возможно, варианты могли спросить у зарубежных коллег. Добровольцев кликнули. Но как насчет заразной среды?
no subject
Date: 2021-08-30 05:55 am (UTC)вот 3 фазу файзера проводили в 6 или 7 странах, где вспышка, причем пару месяцев. Спутник проверяли в Бразилии и Чили.
а стадию 1-2 (безопасность, иммуногенность, примущественно) можно и у себя.
с вариантами вируса тоже проблем нет, это пересылается. а для псевдовирусов надо только мутации знать, остальное синтезируется.
no subject
Date: 2021-08-31 01:34 am (UTC)